Search results
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of ...
KSAN - KLST San Angelo· 5 days agoAlkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 days agoAlkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with ...
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived...
Morningstar· 7 days agoFood and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Zacks via Yahoo Finance· 7 days agoAlkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate...
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary...
Morningstar· 5 days agoCentessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing ...
Vistagen's PH15 nasal spray shows promise in pilot study By Investing.com
Investing.com· 4 days agoThe study found that PH15 significantly improved reaction times in sleep-deprived individuals...
Sleep paralysis: Symptoms, causes and treatments
Daily Telegraph· 6 days ago“While sleep paralysis can indeed be frightening, it is generally harmless,” confirms Rauf. “However, it can be associated with various underlying...
3 No-Brainer Stocks to Buy With $300 Right Now
Motley Fool via Yahoo Finance· 5 days agoFor Jazz, this includes the commercial launch of Avadel Pharmaceuticals' Lumryz as a treatment for cataplexy or excessive daytime sleepiness in adults...
Cwm LLC Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
ETF DAILY NEWS· 4 days agoCwm LLC trimmed its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm ...
Brokerages Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) PT at $40.63
ETF DAILY NEWS· 4 days agoHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are currently covering the company, ...
